MT Newswires35d agoneutral
Nike Fourth-Quarter Revenue Slips as Expected Tariff Refunds Boost EarningsNike's (NKE) fiscal fourth-quarter revenue slipped year-over-year, while the sportswear company's ea
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
529last 24h
2510last 7d
482● bullish (7d)
257● bearish (7d)
197publishers
Bloomberg41d agoneutral
Nike Joins Alphabet, Walmart in Hiring a CFO From the Outside(Bloomberg) -- Moving from Pfizer Inc. to Nike Inc. may seem like an unusual career shift for a finance chief. For David Denton, it marks a return to the consumer sector after four years in pharmaceuticals.Most Read from BloombergInvestor Who Scored 900% Win in 2008 Crisis Has New Big Short BetGrand Ole Opry House Up For Sale by Owner Ryman HospitalityMicron Shares Soar After AI-Fueled Forecast Shatters ProjectionsStocks Slide as Wall Street Gets AI Wake-Up Call: Markets WrapStocks Erase Gains a
Stocktwits42d agoneutral
NKE Stock Gains 2% After-Hours As Nike Names New CFO, Reaffirms Outlook — Retail Calls Leadership Transition ‘Promising’Nike announced a CFO transition and said fourth-quarter results remain on track, excluding a one-time tariff refund benefit.
The Wall Street Journal42d agoneutral
Nike Names Pfizer’s Denton as Next CFODavid Denton’s appointment, effective Aug. 17, comes as the company struggles to execute its turnaround.
Motley Fool44d agoneutral
Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This InsteadThe healthcare company is eyeing opportunities related to artificial intelligence, which it believes can enhance its operations.
The Wall Street Journal44d agoneutral
Healthcare Investors GHO, CBC Weigh New Global Fund to Tap Into Asia’s BoomGlobal Healthcare Opportunities and CBC Group discussed launching a new global fund after their merger, the firms’ heads said, as the healthcare investors move to tap into Asia’s rise as an innovation hub.
Reuters Videos49d agoneutralVIDEO
Big pharma taps UK playbook to pressure Europe on drug prices<body><p>STORY: Big pharma is receiving pushback from European capitals on drug pricing. </p><p>So they’re turning to a playbook that brought them success in the UK.</p><p>Making threats to pull investment plans to pressure policymakers. </p><p>The industry notched a win when the British government agreed to increase medicine spending as part of a broader deal to avoid U.S.-imposed tariffs. </p><p>The latest nation to face pressure is Germany, which has been debating legislation to tighten spending on medicines. </p><p>A Reuters European Pharma correspondent Maggie Fick said pressure in the last week has ramped up. </p><p>"The CEO of Pfizer wrote a letter to the German chancellor warning that their future investments in the country may be at risk over these proposed changes to pricing laws."</p><p>Meanwhile, AstraZeneca warned that it may not launch new medicines in Germany if these changes go ahead.</p><p>Earlier in June, Eli Lilly announced it would halve a planned $2.7 billion investment, also citing the proposed legislation. </p><p>This bid to cap costs has centered Germany in a broader tussle between drugmakers and European governments that began several months ago.</p><p>That tension has been sharpened by the impact on Europe of U.S. President Donald Trump's pricing push.</p><p>This aims to tie prescription medicine prices in the lucrative U.S. market to lower prices elsewhere, including in Europe.</p><p>Major drugmakers have struck deals with the White House to lower drug costs in exchange for tariff exemptions, adding to pressure for increasing prices elsewhere.</p></body>
24/7 Wall St.54d agoneutral
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for RetireesPfizer (NYSE:PFE) is in the middle of its biggest reinvention in a generation, leaning on the Seagen oncology platform and the freshly closed Metsera obesity assets to offset a COVID revenue cliff and looming patent losses. With shares at $25.60 and yielding nearly 7%, the only question that matters for income investors is whether that ... This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees
MarketBeat54d agoneutral
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionGSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.
Zacks62d agoneutral
Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Motley Fool65d agoneutral
Is Pfizer the Perfect Stock to Own with Kevin Warsh Heading the Fed?Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.
Investing.com65d agoneutral
Could GLP-1 drugs become oncology’s next big opportunity?Investing.com -- GLP-1 weight-loss and diabetes drugs may have a future role in cancer prevention and treatment, according to new research highlighted by Citi ahead of the 2026 American Society of Clinical Oncology (ASCO) meeting, adding another potential growth avenue to an already booming drug class.
Investor's Business Daily66d agoneutral
How S&P 500 Giant Pfizer Is Tackling Hard-To-Treat CancersPfizer said Sunday its Braftovi-tied regimen nearly doubled the length of time colon cancer patients lived without getting sicker.
Financial Times66d agoneutral
Growing US reliance on Chinese biotechs prompts national security fearsLawmakers and some investors are warning about the growing reliance of US pharmaceutical companies on China, raising the prospect of national...
Barrons.com74d agoneutral
Fed Hawks Now Rule. Will Warsh Go Along with Them?As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX.
Yahoo Finance Video74d agoneutralVIDEO
Scott Melker explains why the Fed was secretly designed for banksScott Melker discusses the history and structure of the Federal Reserve and presents bitcoin as a decentralized alternative. “The Daily Wolf with Scott Melker” airs on Yahoo Finance every day at 12:00 p.m. Tune in for your daily dose of all things crypto.Make sure to also check out Yahoo Finance's new crypto hub to find the latest crypto-related news.
Bloomberg77d agoneutral
Value Stocks With Earnings Strength Post 3,500% Run Since 2000(Bloomberg) -- Turns out, loading up on technology giants isn’t the only route to better returns. Value companies, too, stand a decent chance of trouncing the market — as long as several conditions are met. Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Threatens Iran With ‘Bi
Moby83d agoneutral
Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call SummaryMoby summary of Protalix BioTherapeutics, Inc.'s Q1 2026 earnings call
MarketBeat83d agoneutral
Valneva Q1 Earnings Call HighlightsValneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer. Chief Executive Officer Thomas Lingelbach
Benzinga83d agoneutral
Transcript: Valneva Q1 2026 Earnings Conference CallOn Wednesday, Valneva (NASDAQ:VALN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://edge.media-server.com/mmc/p/xbkzgkz7 Summary Valneva SE reported first-quarter revenues of approximately €30 million, with a decline from the previous
Pharma Voice85d agoneutral
How tough is it getting for vaccine makers in the U.S.?As federal policy chills domestic demand, some companies are increasingly leaning on sales from international markets.
TheStreet90d agoneutral
Pfizer’s newer medicines carry more weight in Q1Pfizer’s first-quarter results gave investors a clearer view of how much work the drugmaker’s newer portfolio is doing as the company continues moving away from its pandemic-era sales base. In a report given to TheStreet, Pfizer said revenue rose from a year earlier, helped by recently launched and ...
MarketBeat90d agoneutral
Novavax Q1 Earnings Call HighlightsNovavax (NASDAQ:NVAX) executives used the company’s first-quarter 2026 earnings call to highlight continued progress in reshaping the business around partner-driven revenue, a leaner operating model, and selective internal R&D designed to seed additional collaborations. Strategy centered on par
Moby91d agoneutral
Pfizer Inc. Q1 2026 Earnings Call SummaryMoby summary of Pfizer Inc.'s Q1 2026 earnings call
The Wall Street Journal91d agoneutral
Pfizer CEO Says Digging Out of Post-Covid Hole Will Take a Few More YearsPfizer Chief Executive Albert Bourla is battling impending expirations for some blockbuster-drug patents and the precipitous decline of the company's Covid franchise, but he has put a date on when the company will return to consistent growth: 2029. Bourla said Tuesday he expects Pfizer will post high-single-digit average revenue growth annually from 2029 through 2033. “Products are losing patents, and we have a clear line of sight on growth starting in '29,” Bourla said in an interview after the company reported better-than-expected first-quarter results.
Reuters91d agoneutral
Pfizer pins post 2028 return to growth on new obesity and cancer drugsMay 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine. The New York-based drugmaker also beat Wall Street expectations for first-quarter revenue and profit, buoyed by strong demand for its blood thinner Eliquis and recently acquired products, as it faces looming patent expirations and fading COVID produ
MarketBeat92d agoneutral
BioNTech Q1 Earnings Call HighlightsBioNTech (NASDAQ:BNTX) executives used the company’s first-quarter 2026 earnings call to highlight a strategy centered on combination oncology therapies, provide updates on late-stage clinical programs, and outline capital allocation plans that include a $1 billion ADS share repurchase program and m
Zacks92d agoneutral
Pfizer (PFE) Reports Q1 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Pfizer (PFE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
The Wall Street Journal92d agoneutral
Pfizer Posts Better-Than-Expected Revenue, ProfitHigher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Zacks92d agoneutral
Pfizer (PFE) Q1 Earnings and Revenues Top EstimatesPfizer (PFE) delivered earnings and revenue surprises of +5.63% and +4.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?